• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, January 30, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

New genetic culprit suspected in the onset of pancreatic cancer

Bioengineer by Bioengineer
November 30, 2022
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

New research out of VCU Massey Cancer Center points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer. Recently published in Cell Reports, the findings could alter the scientific understanding of this deadly disease and inform the establishment of novel treatments.

Azeddine Atfi

Credit: VCU Massey Cancer Center

New research out of VCU Massey Cancer Center points to the inactivation of a previously unidentified gene as a likely culprit in the development of pancreatic cancer. Recently published in Cell Reports, the findings could alter the scientific understanding of this deadly disease and inform the establishment of novel treatments.

The findings hold implications for the targeted treatment of pancreatic ductal adenocarcinoma (PDAC), which accounts for the vast majority of all pancreatic tumors and is the fourth-leading cause of cancer-related deaths worldwide. Most patients are diagnosed at an advanced stage when the disease is already inoperable and there are no effective therapies.

Extensive research has demonstrated that mutations in the KRAS gene play an enormous role in the formation and growth of pancreatic cancer. Approximately 85-90% of all pancreatic tumors have a KRAS mutation.

“Given its high incidence at very early stages of the disease, mutational activation of KRAS has been hypothesized as the key genetic driver for pancreatic cancer,” said study corresponding author Azeddine Atfi, Ph.D., leader of the Cancer Biology research program who holds the Mary Anderson Harrison Distinguished Professorship in Cancer Research at Massey.

However, there is a substantial fraction — around 10-15% — of PDAC tumors that harbors an offset of the conventional KRAS mutation, characterized as “wild-type KRAS.” This suggests that in many cases alternate genetic drivers are responsible for the development of cancer.

Atfi’s new research suggests that the inactivation of NF1 — a gene known as Neurofibromin-1 that holds natural tumor-suppressing functions — could be instrumental in the onset of pancreatic cancer, either in tandem with KRAS, bolstering its cancer-driving properties, or even before any mutations occur in the KRAS gene, in partnership with TP53, the most inactivated tumor suppressor gene in human malignancies.

Atfi and his collaborators determined that removing NF1 in mice without KRAS mutations directly resulted in the early developmental stages of pancreatic tumors, but also enhanced the cancer-driving function of KRAS in mice with mutations.

“We found that genetic inactivation of NF1 dramatically accelerates the formation and progression of KRAS-mediated pancreatic cancer,” said Atfi, who is also a professor in the Department of Biochemistry and Molecular Biology at the VCU School of Medicine. “This study raises the provocative possibility that targeting NF1 in mutant KRAS-bearing pancreatic tumors might create vulnerabilities that could be exploited for therapeutic advantage.”

Additionally, the researchers observed a strong association between NF1 and p53, another protein widely known for its tumor-suppressing functions. They found that the simultaneous inactivation of both NF1 and p53 directly correlated to pancreatic cancer growth, regardless of any mutations in the KRAS gene.

“The notion that the combined inactivation of NF1 and p53 represents an alternative initiating event in PDAC provides an unprecedented platform for the future identification of novel targeted treatment options for pancreatic cancer,” Atfi said.

Atfi collaborated on this research with Creighton Friend and Eric Hurwitz of the VCU School of Medicine; Parash Parajuli, Ph.D., Gopalakrishnan Ramakrishnan, Pura Singh, and Keli Xu, Ph.D., of the University of Mississippi Medical Center; Celine Prunier of the Sorbonne Université; and Mohammed Razzaque, M.B.B.S., Ph.D., of the Lake Erie College of Osteopathic Medicine.



Journal

Cell Reports

DOI

10.1016/j.celrep.2022.111623

Article Title

NF1 loss of function as an alternative initiating event in pancreatic ductal adenocarcinoma

Article Publication Date

8-Nov-2022

COI Statement

The authors declare no competing interests

Share12Tweet8Share2ShareShareShare2

Related Posts

Genetic mixing between warm-adapted and cool-adapted species can reduce the risk of extinction due to climate change

Mixing between species reduces vulnerability to climate change

January 30, 2023
Turnersuchus hingleyae

New ancient ‘marine crocodile’ discovered on UK’s Jurassic Coast – and it’s one of the oldest specimens of its type ever found

January 30, 2023

Antioxidants from mitochondria protect cells from dying

January 30, 2023

A research led from ITEFI-CSIC achieves inhibition of cancer cell migration in vitro after low intensity ultrasound irradiation, allowing a controlled modification of the tumor cells biodynamics without damage

January 30, 2023

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    64 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

KAIST presents a fundamental technology to remove metastatic traits from lung cancer cells​

Mixing between species reduces vulnerability to climate change

NSF’s NCSES releases report on diversity trends in STEM workforce and education

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 43 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In